PE20010151A1 - Nuevas formas cristalinas de un antibiotico macrolido - Google Patents

Nuevas formas cristalinas de un antibiotico macrolido

Info

Publication number
PE20010151A1
PE20010151A1 PE2000000459A PE0004592000A PE20010151A1 PE 20010151 A1 PE20010151 A1 PE 20010151A1 PE 2000000459 A PE2000000459 A PE 2000000459A PE 0004592000 A PE0004592000 A PE 0004592000A PE 20010151 A1 PE20010151 A1 PE 20010151A1
Authority
PE
Peru
Prior art keywords
compound
crystalline forms
new crystalline
macrolide antibiotic
refers
Prior art date
Application number
PE2000000459A
Other languages
English (en)
Spanish (es)
Inventor
Robert John Rafka
Barry James Morton
Douglas John Meldrum Allen
Colman Brendan Ragan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010151A1 publication Critical patent/PE20010151A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2000000459A 1999-05-18 2000-05-16 Nuevas formas cristalinas de un antibiotico macrolido PE20010151A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13464499P 1999-05-18 1999-05-18

Publications (1)

Publication Number Publication Date
PE20010151A1 true PE20010151A1 (es) 2001-02-08

Family

ID=22464300

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000459A PE20010151A1 (es) 1999-05-18 2000-05-16 Nuevas formas cristalinas de un antibiotico macrolido

Country Status (43)

Country Link
US (1) US6583274B1 (enExample)
EP (1) EP1189912B1 (enExample)
JP (1) JP3897983B2 (enExample)
KR (1) KR100474229B1 (enExample)
CN (1) CN1203084C (enExample)
AP (1) AP2001002325A0 (enExample)
AR (1) AR020030A1 (enExample)
AT (1) ATE392427T1 (enExample)
AU (1) AU772283B2 (enExample)
BG (1) BG106150A (enExample)
BR (1) BR0011300A (enExample)
CA (1) CA2372206C (enExample)
CZ (1) CZ20014120A3 (enExample)
DE (1) DE60038610T2 (enExample)
DK (1) DK1189912T3 (enExample)
DZ (1) DZ3043A1 (enExample)
EA (1) EA003417B1 (enExample)
ES (1) ES2302689T3 (enExample)
GT (1) GT200000072A (enExample)
HK (1) HK1045521B (enExample)
HN (1) HN2000000056A (enExample)
HR (1) HRP20010849A2 (enExample)
HU (1) HUP0201341A3 (enExample)
IL (2) IL145946A0 (enExample)
IS (1) IS6127A (enExample)
MA (1) MA26735A1 (enExample)
MX (1) MXPA01011914A (enExample)
MY (1) MY133397A (enExample)
NO (1) NO320195B1 (enExample)
NZ (1) NZ514765A (enExample)
OA (1) OA11876A (enExample)
PA (1) PA8495001A1 (enExample)
PE (1) PE20010151A1 (enExample)
PL (1) PL353316A1 (enExample)
PT (1) PT1189912E (enExample)
SK (1) SK16472001A3 (enExample)
TN (1) TNSN00103A1 (enExample)
TW (1) TWI225066B (enExample)
UA (1) UA67842C2 (enExample)
UY (1) UY26144A1 (enExample)
WO (1) WO2000069874A1 (enExample)
YU (1) YU76601A (enExample)
ZA (1) ZA200109420B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
ATE243703T1 (de) * 2000-01-27 2003-07-15 Pfizer Prod Inc Antibiotische azalid-zusammensetzungen
CA2445306C (en) * 2001-04-27 2008-02-12 Pfizer Products Inc. Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
EP1435359A1 (en) * 2002-12-31 2004-07-07 Alembic Limited A process for the purification of roxithromycin
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
JP5437394B2 (ja) * 2009-01-30 2014-03-12 グラクソ グループ リミテッド 抗炎症性マクロライド
EP2402355A1 (en) * 2010-07-01 2012-01-04 Novartis AG Crystalline anhydrous forms II and III of Tulathromycin
EP2736915A1 (en) 2011-07-27 2014-06-04 Farma GRS, d.o.o. New crystalline forms of tulathromycin
CN106008622A (zh) * 2016-08-02 2016-10-12 海门慧聚药业有限公司 泰拉霉素新晶型及其制备
CN109942652B (zh) * 2017-12-21 2022-04-26 洛阳惠中兽药有限公司 一种莱柯霉素晶型ⅰ及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.

Also Published As

Publication number Publication date
IL145946A (en) 2007-06-17
PL353316A1 (en) 2003-11-17
UA67842C2 (uk) 2004-07-15
CA2372206C (en) 2006-01-10
NZ514765A (en) 2004-05-28
CN1351607A (zh) 2002-05-29
HN2000000056A (es) 2001-02-02
TWI225066B (en) 2004-12-11
US6583274B1 (en) 2003-06-24
EA003417B1 (ru) 2003-04-24
ZA200109420B (en) 2002-11-15
KR20020007415A (ko) 2002-01-26
AU772283B2 (en) 2004-04-22
ATE392427T1 (de) 2008-05-15
PA8495001A1 (es) 2002-02-21
DE60038610T2 (de) 2009-06-25
JP3897983B2 (ja) 2007-03-28
CN1203084C (zh) 2005-05-25
JP2002544283A (ja) 2002-12-24
HK1045521B (zh) 2005-12-09
GT200000072A (es) 2001-11-08
AR020030A1 (es) 2002-03-27
EP1189912A1 (en) 2002-03-27
DE60038610D1 (de) 2008-05-29
YU76601A (sh) 2004-09-03
CZ20014120A3 (cs) 2003-01-15
OA11876A (en) 2006-03-27
HK1045521A1 (en) 2002-11-29
AU3572900A (en) 2000-12-05
WO2000069874A1 (en) 2000-11-23
IL145946A0 (en) 2002-07-25
CA2372206A1 (en) 2000-11-23
BG106150A (bg) 2002-05-31
SK16472001A3 (sk) 2003-02-04
BR0011300A (pt) 2002-02-26
UY26144A1 (es) 2000-12-29
NO20015598L (no) 2002-01-08
HUP0201341A2 (en) 2002-08-28
ES2302689T3 (es) 2008-08-01
TNSN00103A1 (fr) 2005-11-10
HUP0201341A3 (en) 2003-03-28
NO320195B1 (no) 2005-11-14
EP1189912B1 (en) 2008-04-16
HRP20010849A2 (en) 2003-04-30
MXPA01011914A (es) 2002-05-06
AP2001002325A0 (en) 2001-12-31
MA26735A1 (fr) 2004-12-20
DK1189912T3 (da) 2008-06-30
MY133397A (en) 2007-11-30
IS6127A (is) 2001-10-26
PT1189912E (pt) 2008-05-16
EA200100984A1 (ru) 2002-06-27
NO20015598D0 (no) 2001-11-16
DZ3043A1 (fr) 2004-03-27
KR100474229B1 (ko) 2005-03-08

Similar Documents

Publication Publication Date Title
ES2207403B1 (es) Preparacion de azitromicina en su forma dihidrato cristalina.
Lahari et al. Design and synthesis of novel isatin derivatives as potent analgesic, anti-inflammatory and antimicrobial agents
RU2015137928A (ru) Полиморфные и псевдоплиморфные формы фармацевтического соединения
AR043547A1 (es) Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
CA2286511A1 (en) Novel macrolide derivatives
BG66200B1 (bg) Макролидни солвати
ES2206082T1 (es) Venlafaxina base cristalina y nuevos polimorfismos de hidrocloruro de venlafaxina y procedimientos para su preparacion.
FI68058C (fi) Foerfarande foer framstaellning av 4''-deoxi-4''-acylamidoderivat av oleandomycin erytromycin och erytromycinkarbonat anvaendbara som antibiotika
TW200512214A (en) Avermectin B1 and avermectin B1 monosaccharide derivatives having an alkoxymethyl substituent in the 4"-or 4'-position
ES8104323A1 (es) Un procedimiento para obtener 2,6-diaminonebularinas
RU2106353C1 (ru) Соли 5'-н-фосфоната 3'- азидо-3'-дезокситимидина, являющиеся специфическими ингибиторами продукции вируса иммунодефицита человека вич-1 и вич-2
CA2054895A1 (en) 7-acyl-3-(substituted carbamoyloxy) cephem compounds and process for their preparation
FI903692A0 (fi) Salter av n5, n10-metylen-5,6,7,8- tetrahydrofolsyra.
ES2556135T3 (es) Derivados de caprazeno-1'''-amida
PE20010287A1 (es) Sal difosfato de un derivado de 4"-sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica
CA2217417A1 (en) 9-n-ethenyl derivatives of 9(s)-erythromycylamine
PE20010155A1 (es) Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas
ES2255871B1 (es) Procedimiento para la obtencion de levofloxacino exento de sales.
DK0493064T3 (da) Deacetylcolchicinderivater
PE13295A1 (es) PROCEDIMIENTO PARA PREPARAR ß-LACTAMA CRISTALINA MONOHIDRATO
CN103130852A (zh) 一种红霉素a衍生物、其制备方法、中间体及应用
CA2256017A1 (en) .beta.,.beta.-disubstituted derivatives of 9-deoxo-9a-n-ethenyl-9a-aza-9a-homoerythromycin a
ES2208110B1 (es) Formas cristalinas de acido fusidico y procedimientos para su obtencion.
Ukhov et al. Synthesis and biological activity of substituted 2-iminobenzo [f] coumarin-3-carboxylic acid amides
WO2004032854A3 (en) Pharmaceutical compositions for treatment of parkinson's disease

Legal Events

Date Code Title Description
FD Application declared void or lapsed